Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Key Stats

• Today's Range: $172.32 to $172.46
• 50-Day Range: $168.70 to $172.36
• 52-Week Range: $21.83 to $172.46
• Volume: 1.99 million shs
• Average Volume: 1.09 million shs
• Market Capitalization: $6.58 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RETA Stock Analysis - Frequently Asked Questions

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its quarterly earnings results on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.32) by $0.35. The firm's revenue was up 428.6% on a year-over-year basis.

When did Reata Pharmaceuticals IPO?

Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS) and Sarepta Therapeutics (SRPT).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 10/09/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RETA
• CUSIP: N/A
• CIK: 1358762
• Web: www.reatapharma.com
• Phone: (972) 865-2219
• Fax: N/A
• Employees: 321
• Year Founded: 2002

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-311,900,000.00
• Net Margins: N/A
• Pretax Margin: -373.40%
• Return on Equity: -922.50%
• Return on Assets: -73.39%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 3.21
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $23.48 million
• Price / Sales: 280.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.79) per share
• Price / Book: -96.29

Miscellaneous

• Outstanding Shares: 38,150,000
• Free Float: 27,926,000
• Market Cap: $6.58 billion
• Optionable: Optionable
• Beta: 1.42